ABSTRACT
Dilept eliminated learning disturbances in the extrapolation avoidance test, caused by chronic injections of scopolamine alone and in combination with madopar to rats. Dilept improved the dynamics of training and parameters of spatial memory impaired by olfactory bulbectomy (operation causing hypofunction of the central cholinergic system). The detected choline-positive effect of dilept together with pronounced dopaminergic activity necessitate its further development as a drug effective in positive and negative symptoms of schizophrenia and psychotic manifestations of Alzheimer's disease.
Subject(s)
Memory/drug effects , Neurotensin/analogs & derivatives , Alzheimer Disease/drug therapy , Animals , Avoidance Learning/drug effects , Benserazide/pharmacology , Drug Combinations , Levodopa/pharmacology , Male , Mice , Mice, Inbred Strains , Muscarinic Antagonists/pharmacology , Neurotensin/administration & dosage , Olfactory Bulb/surgery , Peptides/administration & dosage , Rats , Rats, Wistar , Receptors, Muscarinic/drug effects , Schizophrenia/drug therapy , Scopolamine/pharmacology , Space Perception/drug effectsABSTRACT
We studied the effects of a new dipeptide neuroleptic Dilept (N-caproyl-L-prolyl-L-tyrosine methyl ester) on activity of neurotransmitter systems in the brain. Dilept possessed antidopamine, glutamate modulatory, and cholinomimetic properties. These data indicate that Dilept is of potential efficacy in relieving positive and negative symptoms of schizophrenia.
